Moshe Mittelman

6.8k citations

221 papers · 4.9k · 1 hit paper · h-index 36

Impact in

Hematology top 0.2%
- Acute Myeloid Leukemia Research
- Erythropoietin and Anemia Treatment
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma Research and Treatments
- Iron Metabolism and Disorders
Genetics top 0.5%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders

Papers in

Hematology 147
- Acute Myeloid Leukemia Research 80
- Erythropoietin and Anemia Treatment 39
- Multiple Myeloma Research and Treatments 24
Genetics 53
- Myeloproliferative Neoplasms: Diagnosis and Treatment 23
- Hemoglobinopathies and Related Disorders 17
- Chronic Lymphocytic Leukemia Research 16

Co-authors: Drorit Neumann (35 shared papers)Howard S. Oster (37 shared papers)Max Gassmann (7 shared papers)Aliza Zeidman (21 shared papers)Alan N. Schechter (8 shared papers)Odelia Katz (11 shared papers)Amos Menahem Cohen (16 shared papers)Meir Djaldetti (19 shared papers)
Journals: Blood (33 papers)Acta Haematologica (13 papers)Leukemia Research (12 papers)Haematologica (10 papers)British Journal of Haematology (9 papers)
Partner nations: Israel United States Netherlands

In The Last Decade

Moshe Mittelman

212 papers receiving 4.7k citations

Moshe Mittelman's Hit Papers

align trajectories log scale

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet 2013 · 535 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2013 Blood

Peers

Countries citing papers authored by Moshe Mittelman

Since Specialization

Citations

This map shows the geographic impact of Moshe Mittelman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Moshe Mittelman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Moshe Mittelman more than expected).

Fields of papers citing papers by Moshe Mittelman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Moshe Mittelman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Moshe Mittelman. The network helps show where Moshe Mittelman may publish in the future.

Co-authors

The 25 scholars most cited alongside Moshe Mittelman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Moshe Mittelman Line = papers co-authored together Moshe Mittelman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 221 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet Blood ·Luca Malcovati, Eva Hellström‐Lindberg, David Bowen, Lionel Adès, Jaroslav Čermák, Consuelo del Cañizo, Matteo Giovanni Della Porta, Pierre Fenaux Hit paper breakdown →	2013	535
2	A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q Blood ·Pierre Fenaux, Aristoteles A. N. Giagounidis, Dominik Selleslag, Odile Beyne‐Rauzy, Ghulam Mufti, Moshe Mittelman, Petra Muus, Peter A.W. te Boekhorst	2011	410
3	Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents Journal of Clinical Oncology ·Valeria Santini, Antonio Medina Almeida, Aristoteles A. N. Giagounidis, Stefanie Gröpper, Anna T Jonasova, Norbert Vey, Ghulam J. Mufti, Rena J. Buckstein	2016	191
4	Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models Proceedings of the National Academy of Sciences ·Moshe Mittelman, Drorit Neumann, Alpha Peled, Pazit Kanter, Nechama Haran‐Ghera	2001	138
5	p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q) Haematologica ·Leonie Saft, Masoud Karimi, Mehran Ghaderi, András Matolcsy, G J Mufti, Austin Gladston Kulasekararaj, Gudrun Göhring, Aristoteles A. N. Giagounidis	2014	119
6	Erythropoietin directly stimulates osteoclast precursors and induces bone loss The FASEB Journal ·Sahar Hiram‐Bab, Tamar Liron, Naamit Deshet‐Unger, Moshe Mittelman, Max Gassmann, Martina Rauner, Kristin Franke, Ben Wielockx	2015	101
7	Macrophages as novel target cells for erythropoietin Haematologica ·Lawrence M. Lifshitz, Galit Tabak, Max Gassmann, Moshe Mittelman, Drorit Neumann	2010	88
8	A common protein binds to two silencers 5′ to the human β-globin gene Nucleic Acids Research ·Patricia E. Berg, Donna Marie Williams, Ruo-Lan Qian, Roger B. Cohen, Shi-Xian Cao, Moshe Mittelman, Alan N. Schechter	1989	87
9	Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study Leukemia ·Reinhard Stauder, Ge Yu, Karin A. Koinig, Timothy Bagguley, Pierre Fenaux, Argiris S. Symeonidis, Guillermo Francisco Sanz, Jaroslav Čermák	2018	86
10	DNA sequence variation in a negative control region 5' to the beta- globin gene correlates with the phenotypic expression of the beta s mutation Blood ·Jacques Élion, PE Berg, Claudine Lapouméroulie, G Trabuchet, Moshe Mittelman, Rajagopal Krishnamoorthy, Alan N. Schechter, D Labie	1992	82
11	The Two Common Mutations Causing Factor XI Deficiency in Jews Stem From Distinct Founders: One of Ancient Middle Eastern Origin and Another of More Recent European Origin Blood ·Hava Peretz, Avital Mulai, Sali Usher, Ariella Zivelin, Avihai Segal, Zahavi Weisman, Moshe Mittelman, Hannah Lupo	1997	80
12	Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia Blood ·Michael John Dickinson, Honar Cherif, Pierre Fenaux, Moshe Mittelman, Amit K. Verma, Maria Socorro O Portella, Paul Burgess, Pedro Marques Ramos	2018	77
13	Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial The Lancet Haematology ·Moshe Mittelman, Uwe Platzbecker, Boris Vladimirovich Afanasyev, Sebastian Grosicki, Raymond S. M. Wong, Αchilles Anagnostopoulos, Benjamin Brenner, Claudio Denzlinger	2017	75
14	Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models Journal of Endocrinology ·Odelia Katz, Matthew Stuible, N. Golishevski, Lilach Lifshitz, Michel L. Tremblay, Max Gassmann, Moshe Mittelman, Drorit Neumann	2010	73
15	Agonists to the A3 adenosine receptor induce G-CSF production via NF-κB activation Experimental Hematology ·Sara Bar‐Yehuda, Lea Madi, Dana Barak, Moshe Mittelman, Eti Ardon, Avivit Ochaion, Shira Cohn, Pnina Fishman	2002	66
16	Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma British Journal of Haematology ·Irit Mazza Avivi, Roi Balaban, Tamir Shragai, Gabi Sheffer, M. Morales, Anat Aharon, Noa Lowenton‐Spier, Svetlana Trestman	2021	64
17	Predicting infections in high‐risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: Aretrospective multicenter study American Journal of Hematology ·Drorit Grizim Merkel, Kalman Filanovsky, Anat Gafter‐Gvili, Liat Vidal, Ariel Aviv, Moshe E. Gatt, Itay Silbershatz, Yair Herishanu	2012	63
18	MOR: a simulation‐based assessment centre for evaluating the personal and interpersonal qualities of medical school candidates Medical Education ·Amitai Ziv, Orit Rubin, Avital Moshinsky, Naomi Gafni, Moshe Kotler, Yaron Dagan, Dov A. Lichtenberg, Yoseph A. Mekori	2008	59
19	Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes Journal of Clinical Oncology ·Guillermo Garcia‐Manero, Valeria Santini, Antonio Medina Almeida, Uwe Platzbecker, Anna T Jonasova, Lewis R. Silverman, Jose Francisco Falantes, Gianluigi Reda	2021	59
20	Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting Blood ·Moshe Mittelman, Ori Magen, Noam Barda, Noa Dagan, Howard S. Oster, Avi Leader, Ran D. Balicer	2021	58

About Moshe Mittelman

Moshe Mittelman is a scholar working on Hematology, Genetics, Emergency Medicine, Immunology and Oncology, having authored 221 papers that have together received 4.9k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (80 papers), Erythropoietin and Anemia Treatment (39 papers), Multiple Myeloma Research and Treatments (24 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (23 papers), Hematological disorders and diagnostics (18 papers), Hemoglobinopathies and Related Disorders (17 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Erythrocyte Function and Pathophysiology (12 papers). The work is most often cited by research in Hematology (3.2k citations), Genetics (1.4k citations), Emergency Medicine (251 citations), Oncology (543 citations) and Orthopedics and Sports Medicine (154 citations). Moshe Mittelman has collaborated with scholars based in Israel, United States and Netherlands. Frequent co-authors include Drorit Neumann, Howard S. Oster, Max Gassmann, Aliza Zeidman, Alan N. Schechter, Odelia Katz, Amos Menahem Cohen, Meir Djaldetti, Alpha Peled and Nechama Haran‐Ghera. Their work appears in journals such as Blood, Acta Haematologica, Leukemia Research, Haematologica and British Journal of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Moshe Mittelman

Impact in

Papers in i

In The Last Decade

Moshe Mittelman

Moshe Mittelman's Hit Papers

Peers

Countries citing papers authored by Moshe Mittelman

Fields of papers citing papers by Moshe Mittelman

All Works

About Moshe Mittelman

Explore authors with similar magnitude of impact

Papers in